EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. (EYPT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · EYPT · as of Mar 31, 2025
Ownership Breakdown
157
Institutional Holders
▲ 7 vs Q4
$401.20M
Total Inst. Value
▼ $152.16M vs Q4
83.84M
Shares Outstanding
freeFloat 84.05%
74.07M
13F Shares Held
▼ 360,465 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
EYPT largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CORMORANT ASSET MANAGEMENT, LP laboratory analytical instruments | 8.32M | 11.93% | 11.93% | $45.12B | May 15, 2025 | — held |
SUVRETTA CAPITAL MANAGEMENT, LLC laboratory analytical instruments | 6.80M | 9.75% | 9.75% | $36.88B | May 15, 2025 | ▲ 21.0K |
ADAGE CAPITAL PARTNERS GP, L.L.C. laboratory analytical instruments | 6.20M | 8.89% | 8.89% | $33.60B | May 15, 2025 | ▲ 450.0K |
BLACKROCK, INC. laboratory analytical instruments | 5.72M | 8.20% | 8.20% | $31.01B | May 2, 2025 | ▲ 440.7K |
FRANKLIN RESOURCES INC laboratory analytical instruments | 4.15M | 5.95% | 5.95% | $22.49B | May 13, 2025 | ▲ 12.3K |
FEDERATED HERMES, INC. laboratory analytical instruments | 4.09M | 5.86% | 5.86% | $22.14B | May 8, 2025 | ▲ 378.1K |
VANGUARD GROUP INC laboratory analytical instruments | 3.83M | 5.50% | 5.50% | $20.78B | May 9, 2025 | ▲ 31.1K |
TCG CROSSOVER MANAGEMENT, LLC laboratory analytical instruments | 3.57M | 5.12% | 5.12% | $19.36B | May 14, 2025 | — held |
RA CAPITAL MANAGEMENT, L.P. laboratory analytical instruments | 3.18M | 4.56% | 4.56% | $17.25B | May 15, 2025 | — held |
CITADEL ADVISORS LLC laboratory analytical instruments | 2.29M | 3.28% | 3.28% | $12.39B | May 15, 2025 | ▼ 180.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
25
Increased
+3.66M shares1
New Positions
first time holders16
Decreased
−1.40M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.26M
+3.66M / −1.40M
Net new holders
+10
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
EYPT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
4
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Elston George Chief Financial Officer | May 25, 2026 | Tax Withhold | 3,627 | $12.93 | $46.9K | 91.7K | Form 4 ↗ |
Ribeiro Ramiro Chief Medical Officer | Apr 17, 2026 | Sale | 2,437 | $15.00 | $36.6K | 0 | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 76,766 | $13.11 | $1.01M | 177.4K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 97,500 | $20.40 | $1.99M | 97.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 97,500 | $20.40 | $1.99M | 82.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 52,500 | $13.13 | $689.3K | 52.5K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 52,500 | $13.13 | $689.3K | 7.8K | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 23, 2026 | J-Other | 76,766 | $13.11 | $1.01M | 986 | Form 4 ↗ |
Duker Jay S. President and CEO | Mar 16, 2026 | Purchase | 1,500 | $13.15 | $19.7K | 100.7K | Form 4 ↗ |
Elston George Chief Financial Officer | Mar 2, 2026 | Gift | 5,000 | — | — | 87.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
EyePoint Pharmaceuticals, Inc. (EYPT) is primarily owned by institutional investors, who hold approximately 88.3% of total shares outstanding. Company insiders own approximately 15.95%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of EyePoint Pharmaceuticals, Inc. is CORMORANT ASSET MANAGEMENT, LP, holding approximately 8.32 million shares — equal to 11.93% of outstanding shares — as of March 31, 2025.
A total of 157 institutional investors currently hold EYPT stock, with a combined institutional value of approximately $401,204,469 as of the most recent 13F filing period.
Frequently asked questions
EYPT ownershipEyePoint Pharmaceuticals, Inc. (EYPT) is primarily owned by institutional investors, who hold approximately 88.3% of shares. The largest shareholder is CORMORANT ASSET MANAGEMENT, LP with a 11.93% stake. Company insiders hold 15.95%. Data sourced from SEC Form 13F as of March 31, 2025.